Cargando…
Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives
Diabetes increases the prevalence of heart failure by 6–8-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187922/ https://www.ncbi.nlm.nih.gov/pubmed/34076247 http://dx.doi.org/10.1042/CS20210052 |
_version_ | 1783705235821166592 |
---|---|
author | Prakoso, Darnel Tate, Mitchel Blasio, Miles J. De Ritchie, Rebecca H. |
author_facet | Prakoso, Darnel Tate, Mitchel Blasio, Miles J. De Ritchie, Rebecca H. |
author_sort | Prakoso, Darnel |
collection | PubMed |
description | Diabetes increases the prevalence of heart failure by 6–8-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with diabetes-induced heart failure. This has led to the development of multiple pharmacological agents that are currently available for clinical use. While fairly effective at delaying disease progression, these treatments do not reverse the cardiac damage associated with diabetes. One potential alternative avenue for targeting diabetes-induced heart failure is the use of adeno-associated viral vector (AAV) gene therapy, which has shown great versatility in a multitude of disease settings. AAV gene therapy has the potential to target specific cells or tissues, has a low host immune response and has the possibility to represent a lifelong cure, not possible with current conventional pharmacotherapies. In this review, we will assess the therapeutic potential of AAV gene therapy as a treatment for diabetic cardiomyopathy. |
format | Online Article Text |
id | pubmed-8187922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81879222021-06-15 Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives Prakoso, Darnel Tate, Mitchel Blasio, Miles J. De Ritchie, Rebecca H. Clin Sci (Lond) Diabetes & Metabolic Disorders Diabetes increases the prevalence of heart failure by 6–8-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with diabetes-induced heart failure. This has led to the development of multiple pharmacological agents that are currently available for clinical use. While fairly effective at delaying disease progression, these treatments do not reverse the cardiac damage associated with diabetes. One potential alternative avenue for targeting diabetes-induced heart failure is the use of adeno-associated viral vector (AAV) gene therapy, which has shown great versatility in a multitude of disease settings. AAV gene therapy has the potential to target specific cells or tissues, has a low host immune response and has the possibility to represent a lifelong cure, not possible with current conventional pharmacotherapies. In this review, we will assess the therapeutic potential of AAV gene therapy as a treatment for diabetic cardiomyopathy. Portland Press Ltd. 2021-06-02 /pmc/articles/PMC8187922/ /pubmed/34076247 http://dx.doi.org/10.1042/CS20210052 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . Open access for this article was enabled by the participation of University of Monash in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with CAUL. |
spellingShingle | Diabetes & Metabolic Disorders Prakoso, Darnel Tate, Mitchel Blasio, Miles J. De Ritchie, Rebecca H. Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title_full | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title_fullStr | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title_full_unstemmed | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title_short | Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
title_sort | adeno-associated viral (aav) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives |
topic | Diabetes & Metabolic Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187922/ https://www.ncbi.nlm.nih.gov/pubmed/34076247 http://dx.doi.org/10.1042/CS20210052 |
work_keys_str_mv | AT prakosodarnel adenoassociatedviralaavvectormediatedtherapeuticsfordiabeticcardiomyopathycurrentandfutureperspectives AT tatemitchel adenoassociatedviralaavvectormediatedtherapeuticsfordiabeticcardiomyopathycurrentandfutureperspectives AT blasiomilesjde adenoassociatedviralaavvectormediatedtherapeuticsfordiabeticcardiomyopathycurrentandfutureperspectives AT ritchierebeccah adenoassociatedviralaavvectormediatedtherapeuticsfordiabeticcardiomyopathycurrentandfutureperspectives |